No of subjects | | 40 | | 388 | | 110 | | 27 | | 191 | | 36 | | 61 | | 143 | | 82 | | 123 | | 283 | | 1484 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Pre-stroke
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Antiplatelet (%) | | 2 (5.0) | | 1 (0.3) | | 0 (0) | | 2 (7.4) | | 1 (0.5) | | 2 (5.6) | | 0 (0) | | 8 (5.6) | | 0 (0) | | 5 (4.1) | | 3 (1.1) | | 24 (1.6) | | <0.0001 |
Anticoagulation (%) | | 0 (0) | | 1 (0.3) | | 2 (1.8) | | 0 (0) | | 0 (0) | | 0 (0) | | 0 (0) | | 0 (0) | | 0 (0) | | 1 (0.8) | | 0 (0) | | 4 (0.3) | | 0.28 |
Antithrombotic (%) | | 2 (5.0) | | 2 (0.5) | | 2 (1.8) | | 2 (7.4) | | 1 (0.5) | | 2 (5.6) | | 0 (0) | | 8 (5.6) | | 0 (0) | | 6 (4.9) | | 3 (1.1) | | 28 (1.9) | | 0.0001 |
Antihypertensive (%) | | 28 (70) | | 186 (47.9) | | 45 (40.9) | | 12 (44.4) | | 97 (50.8) | | 17 (47.2) | | 31 (50.8) | | 70 (48.9) | | 35 (42.7) | | 63 (51.2) | | 98 (34.6) | | 682 (46.0) | | 0.0008 |
Lipid lowering (%) | | 9 (22.5) | | 32 (8.3) | | 1 (0.9) | | 0 (0) | | 20 (10.5) | | 1 (2.8) | | 2 (3.3) | | 18 (12.6) | | 2 (2.4) | | 8 (6.5) | | 7 (2.5) | | 100 (6.7) | | <0.0001 |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
In hospital
| | | | | | | | | | | | | | | | | | | | | | | | | | |
ASU (%) | | 5 (12.5) | | 60 (15.5) | | 42 (38.2) | | 4 (14.8) | | 45 (23.6) | | 13 (36.1) | | 1 (1.6) | | 68 (47.8) | | 53 (64.6) | | 56 (45.5) | | 225 (79.5) | | 572 (38.5) | | <0.0001 |
SRU (%) | | 16 (40.0) | | 84 (21.6) | | 63 (57.3) | | 0 (0) | | 1 (0.5) | | 24 (66.7) | | 3 (4.9) | | 96 (67.1) | | 32 (39.0) | | 55 (44.7) | | 80 (28.3) | | 454 (30.6) | | <0.0001 |
Stroke unit (%) | | 17 (42.5) | | 141 (36.3) | | 90 (81.8) | | 4 (14.8) | | 45 (23.6) | | 29 (80.6) | | 4 (6.6) | | 113 (79.0) | | 82 (100) | | 96 (78.0) | | 234 (82.7) | | 855 (57.6) | | <0.0001 |
Compression stockings (%) | | 35 (87.5) | | 149 (38.4) | | 15 (13.6) | | 6 (22.2) | | 118 (61.8) | | 29 (80.6) | | 41 (67.2) | | 135 (94.4) | | 13 (15.9) | | 16 (13.0) | | 246 (86.9) | | 803 (54.1) | | <0.0001 |
Physiotherapy (%) | | 34 (85.0) | | 326 (84.0) | | 98 (89.1) | | 23 (85.2) | | 168 (88.0) | | 34 (94.4) | | 52 (85.2) | | 127 (88.8) | | 78 (95.1) | | 102 (82.9) | | 249 (88.0) | | 1291 (87.0) | | 0.0009 |
Speech therapy (%) | | 17 (42.5) | | 171 (44.1) | | 28 (25.5) | | 9 (33.3) | | 32 (16.8) | | 19 (52.8) | | 38 (62.3) | | 50 (35.0) | | 18 (22.0) | | 17 (13.8) | | 138 (48.8) | | 537 (36.2) | | <0.0001 |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Post-stroke
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Antiplatelet* (%) | | 16 (57.1) | | 207 (64.7) | | 70 (76.1) | | 19 (76.0) | | 91 (64.5) | | 20 (80.0) | | 22 (73.3) | | 89 (78.8) | | 56 (84.9) | | 67 (84.8) | | 141 (77.5) | | 798 (72.5) | | 0.0001 |
Anticoagulation† (%) | | 3 (25.0) | | 23 (35.4) | | 3 (20.0) | | 2 (100.0) | | 4 (8.2) | | 2 (18.2) | | 9 (29.0) | | 1 (3.6) | | 7 (53.9) | | 7 (15.9) | | 22 (22.5) | | 83 (22.6) | | 0.0002 |
Antithrombotic (%) | | 19 (47.5) | | 230 (59.7) | | 73 (68.2) | | 21 (77.8) | | 95 (50.0) | | 22 (61.1) | | 31 (50.8) | | 90 (63.8) | | 63 (79.8) | | 74 (60.2) | | 163 (58.2) | | 881 (60.0) | | 0.0002 |
Antihypertensive (%) | | 22 (55.0) | | 216 (55.7) | | 46 (41.8) | | 11 (40.7) | | 97 (50.8) | | 21 (58.3) | | 24 (39.3) | | 53 (37.1) | | 39 (47.6) | | 66 (53.7) | | 108 (38.2) | | 703 (47.4) | | 0.0001 |
Lipid lowering (%) | | 8 (20.0) | | 63 (16.2) | | 4 (2.8) | | 0 (0) | | 25 (13.1) | | 1 (2.8) | | 10 (16.4) | | 22 (15.4) | | 5 (6.1) | | 15 (12.2) | | 34 (12.0) | | 187 (12.6) | | 0.0028 |